Madrigal Pharmaceuticals Inc
NASDAQ:MDGL 4:00:00 PM EDT
| Market Cap (Intraday) | 4.67B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $235.96 |
| 50-Day MA | $241.44 |
| 200-Day MA | $201.99 |
Madrigal Pharmaceuticals Inc Stock, NASDAQ:MDGL
200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428
United States of America
Phone: +1.267.824.2827
Number of Employees: 376
Description
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.